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The concentration of long chain polyunsaturated fatty acid (LCPUFA) in the fetal brain
increases dramatically from the third trimester until 18months of life. Several studies have
shown an association between the percentage of maternal plasma docosahexaenoic acid
(DHA) during gestation and development of cognitive functions in the neonate. Since only
very low levels of LCPUFA are synthesized in the fetus and placenta, their primary source
for the fetus is the maternal circulation. Both in vitro and human in vivo studies using
labeled fatty acids have shown preferential transfer of LCPUFA from the placenta to the
fetus compared with other fatty acids, although the mechanisms involved are still uncer-
tain. The placenta takes up circulating maternal non-esteriﬁed fatty acids (NEFA) and fatty
acids released mainly by maternal lipoprotein lipase and endothelial lipase. These NEFA
may enter the cell by passive diffusion or by means of membrane carrier proteins. Once
in the cytosol, NEFA bind to cytosolic fatty acid-binding proteins for transfer to the fetal
circulation or can be oxidized within the trophoblasts, and even re-esteriﬁed and stored
in lipid droplets. Although trophoblast cells are not specialized for lipid storage, LCPUFA
may up-regulate peroxisome proliferator activated receptor-γ (PPARγ) and hence the gene
expression of fatty acid transport carriers, fatty acid acyl-CoA-synthetases and adipophilin
or other enzymes involved in lipolysis, modifying the rate of placental transfer, and metab-
olism. The placental transfer of LCPUFA during pregnancy seems to be a key factor in the
neurological development of the fetus. Increased knowledge of the factors that modify
placental transfer of fatty acids would contribute to our understanding of this complex
process.
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LONG CHAIN POLYUNSATURATED FATTY ACIDS AND
PREGNANCY
Long chain polyunsaturated fatty acids (LCPUFA),mainly docosa-
hexaenoic acid (DHA, 22:6 n−3), are highly concentrated in
the cell membranes of the retina and brain, where they acts
as important modulators of membrane function, neurogenesis,
photoreceptor differentiation, activation of the visual pigment
rhodopsin, the function of ion channels, the activity of several
enzymes, and the levels and metabolism of neurotransmitters and
eicosanoids (Neuringer et al., 1988; Lauritzen et al., 2001; Innis,
2007). During the last trimester of gestation a spurt in brain
growth accompanied by considerable lipid accretion occurs in
the human fetus (Widdowson, 1968; Dobbing and Sands, 1979;
Martínez, 1992). This period, therefore, is critical for the materno-
fetal provision of LCPUFA to the developing central nervous
system.
Numerous observational studies have demonstrated that fatty
acid concentration in both maternal plasma and erythrocytes
increases during pregnancy, as a direct consequence of physiolog-
ical gestational hyperlipidemia (Otto et al., 1997; Matorras et al.,
2001; Vlaardingerbroek and Hornstra, 2004). The concentration
of individual fatty acids increases during gestation, although the
extent differs between acids. The maximum increase is seen in
the concentration of DHA (Stewart et al., 2007). This cannot be
explained simply by the modiﬁcation of dietary habits, and the
most accepted hypothesis is its enhanced mobilization from the
maternal adipose tissue depots, although an increase in the activ-
ity of the enzymes involved in fatty acid synthesis, particularly the
synthesis of DHA, in the mother cannot be excluded. The placenta
also partly regulates the mobilization of fatty acids from adipose
tissue through leptin secretion to the maternal and fetal circu-
lation (Haggarty, 2004), although a leptin resistance situation is
produced at the end of pregnancy.
Despite the increase in the absolute fatty acid concentration
during pregnancy, the levels of both essential fatty acids (EFA, 18:2
n−6 linoleic acid and 18:3 n−3 α-linolenic acid) and LCPUFA,
such as DHA, as a percentage of total fatty acids decreases. This
observation suggests that pregnancy is associated with a reduc-
tion in the relative amounts of EFA and DHA in the maternal
circulation (Al et al., 1995, 2000; Vlaardingerbroek and Hornstra,
2004) emphasizing the importance of these compounds for fetal
development.
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FATTY ACID SUPPLY TO THE FETUS
Physiologically, the fetus may synthesize some saturated fatty acids
(SFA) andmonounsaturated fatty acids (MUFA)de novo fromglu-
cose (Nelson, 1992). However, the fetus depends on the placental
supply of maternal EFA and LCPUFA (especially arachidonic acid,
AA, and DHA). EFA cannot be synthesized by humans and they
have to be consumed in the maternal diet. As regards LCPUFA,
neither the placenta nor the fetus possesses sufﬁcient desaturase
activity to synthesize these fatty acids (Chambaz et al., 1985),which
are considered essential nutrients for the fetus. Although endoge-
nous synthesis is likely to be higher in preterm than in term infants
(Uauy et al., 2000), the amount of LCPUFA produced from EFA
is insufﬁcient to match the in utero accretion rate (Lapillonne and
Jensen, 2009). Therefore, the primary source of LCPUFA for the
fetus is also that of maternal origin.
In vitro experimental studies (Campbell et al., 1997), placen-
tal perfusion studies (Haggarty et al., 1999), and in vivo studies
in pregnant women using fatty acids labeled with stable isotopes
(Larque et al., 2003; Gil-Sanchez et al., 2010) have shown prefer-
ential LCPUFA placental transfer with respect to other fatty acids
(Figure 1). In addition, the percentage of LCPUFA in umbilical
cord plasma lipids is higher than in the maternal plasma lipids
at the time of birth (Crawford et al., 1989; Al et al., 1990; Ruyle
et al., 1990; Berghaus et al., 1998), although, the proportion of
EFA is lower in the neonate than in the mother. This selective
LCPUFA enrichment in the fetal circulation is known as “bio-
magniﬁcation” (Crawford et al., 1976), and highlights the role of
the placenta for the preferential transfer of these compounds to
the fetus. However, the mechanisms involved are still unknown,
and the selective uptake of these compounds by the placenta and
FIGURE 1 | (A) Ratio (%) between placenta and maternal plasma AUC
concentration of 13C-fatty acids administered 4 or 12 h before cesarean
section. (B) Ratio (%) between cord plasma and maternal plasma AUC
concentration of 13C-fatty acids administered 4 or 12 h before cesarean
section. Results are expressed as x¯ ± SEM.T -test, *P<0.05.
even a different rate for lipogenesis/lipolysis within the placenta
have been suggested. The mechanisms involved in the preferential
transfer of DHA across the placenta is a major issue that needs to
be better understood to allow for the design of further nutritional
strategies to improve fatty acid availability to the fetus.
MECHANISMS OF PLACENTAL UPTAKE OF FATTY ACIDS
FROMMATERNAL CIRCULATION
The placenta, like other tissues, may capture non-esteriﬁed fatty
acids (NEFA) and fatty acids released from maternal lipoproteins
by local endothelial lipases (EL). The difference in NEFA concen-
tration between thematernal and fetal circulation increases during
gestation and, at the time of delivery, the maternal NEFA concen-
tration is approximately three times that of the fetus (Haggarty,
2004). The maternal hyperlipidemia that occurs during gestation
also contributes fatty acids to the fetus, following their release from
the maternal lipoproteins by the placental lipoprotein lipase (LPL)
and EL (Figure 2).
TheLPLenzymehas classically beendescribed as being involved
in fatty acid uptake in many tissues, including adipose tissue,
muscle, and placental tissue. LPL is an enzyme that is found in
the placental microvillus membrane in contact with the mater-
nal blood (Waterman et al., 1998), in the trophoblast and also in
isolated macrophages (Bonet et al., 1992). It shows triglyceride
lipase activity and is responsible for TG hydrolysis in chylomi-
crons (CM) and very-low-density lipoproteins (VLDL), releasing
two fatty acids for tissue uptake (Figure 2; Mead et al., 2002;Wang
and Eckel, 2009). In the literature, this is the most widely accepted
mechanism to explain the placental fatty acid uptake process.
Endothelial lipase is a major enzyme in the placenta, regardless
of gestational age. At the end of pregnancy, EL continues to be
expressed while LPL is virtually absent in the trophoblast. How-
ever, in placental vessels, increased expression of both enzymes has
been observed (Gauster et al., 2007). EL mainly has A1 phospholi-
pase activity, releasing the fatty acid from the sn−1 position of the
phospholipids (PL), and producing a lysophospholipid (lyso-PL),
FIGURE 2 | Placental fatty acid uptake process.TG, triglycerides; NEFA,
non-esteriﬁed fatty acids; PL, phospholipids; Lyso-PL, lysophospholipids; LP,
lipoproteins; R, receptor; LPL, lipoprotein lipase; EL, endothelial lipase.
PLA2, phospholipase A2.
Frontiers in Genetics | Epigenomics September 2011 | Volume 2 | Article 57 | 2
Gil-Sánchez et al. Placental fatty acid metabolism
although it also has minimal levels of triglyceride lipase activity
(Choi et al., 2002). Since SFA are found predominantly in the sn−1
position of the PL, while polyunsaturated fatty acids are typically
esteriﬁed in the sn−2 position (Macdonald and Sprecher, 1991),
EL activity might result in enhanced levels of maternal plasma
lyso-PL enriched in LCPUFA. These lyso-PL could be an addi-
tional source of fatty acids for the placenta. This is supported by
reports that lyso-phosphatidylcholine in the brain may be a pre-
ferred physiological carrier of DHA,rather thanNEFA (Thies et al.,
1992; Lagarde et al., 2001). Similarly, lyso-phosphatidylcholine
seems to deliver 13C-DHA more efﬁciently to erythrocytes than
NEFA (Brossard et al., 1997). Furthermore, some authors have also
suggested thatmaternal erythrocytes,which take lyso-PL into their
membranes,may be a potential store of LCPUFA, and a vehicle for
their transport to the placenta (Ghebremeskel et al., 2000).
Magnusson et al. (2004) investigated placental LPL in normal
gestations in comparisonwith gestations complicatedby intrauter-
ine growth restriction (IUGR), insulin dependent diabetes melli-
tus (IDDM), or gestational diabetes mellitus (GDM). This study
demonstrated that the placental LPL activity was reduced by 47%
in IUGR, but increased by 39% in IDDM with respect to the con-
trols. Lindegaard et al. (2006) reported increases in placental LPL
activity in gestations complicated with IDDM in association with
fetal overgrowth. Hence, these studies support the hypothesis that
alterations in LPL contribute to changes in the transport of the
fatty acids to the fetus and, consequently may modify its growth
(Magnusson et al., 2004).
Other lipases that could be involved in the release of fatty
acids from maternal plasma lipoproteins are phospholipase A2
type II, which is mainly expressed in placenta and the choriode-
cidua (Freed et al., 1997), and triacylglycerol hydrolase, with a pH
optimum(6.0) that differs fromLPL,which is expressed in the syn-
cytiotrophoblast microvillus membrane (Waterman et al., 2000).
Part of the phospholipase A2 type II is secreted to the placen-
tal extracellular compartment, where it continues to be active, not
only intracellularly, but also extracellularly (Rice et al., 1998). Also,
the placental tissue shows lipoprotein receptors of HDL, LDL, etc.
(Naoum et al., 1987; Herrera, 2002). Thus, after binding to these
receptors, some lipoproteins can undergo endocytosis to provide
cholesterol to the placenta; this last mechanism could also provide
fatty acids to placental tissue once they are released by the intra-
cellular lipases, although the relevance of this mechanism for the
placental uptake of fatty acids is still uncertain.
FATTY ACID CARRIERS IN PLACENTAL MEMBRANES
Once fatty acids have been released by the lipases as NEFA, they
enter the cell through passive diffusion or by means of mem-
brane carrier proteins known as fatty acid-binding protein plasma
membrane (FABPpm), placental plasma membrane fatty acid-
binding protein (p-FABPpm), fatty acid translocase (FAT/CD36),
and fatty acid transport proteins (FATP-1 to -6; Dutta-Roy, 2000;
Hanebutt et al., 2008; Figure 3). These proteins are located in the
syncytiotrophoblast basal and microvillus membrane, except for
p-FABPpm,which has only been reported in themicrovillusmem-
brane (Campbell et al., 1998). FATPS, FAT/CD36, and FABPpm
have been described in many tissues, but only p-FABPpm seems to
be exclusive to placental tissue (Campbell and Dutta-Roy, 1995).
FIGURE 3 | Figure taken from Hanebutt et al. (2008).Theoretical model
of fatty acid movement across placental tissue. LP, lipoprotein; LPL,
lipoprotein lipase; NEFA, non-esteriﬁed fatty acid; FATP, fatty acid transport
protein; FAT, fatty acid translocase; P-FABPpm, placental plasma membrane
fatty acid binding protein; L-FABP, liver-fatty acid binding protein; H-FABP,
heart-fatty acid binding protein; PPAR, peroxisome proliferator activated
receptor; RXR, retinoid X receptor.
Although the role of these membrane proteins in the placental
fatty acid uptake, metabolism, and transfer process is not com-
pletely understood, it has been suggested that the enrichment of
LCPUFA in the fetal circulation could be related to their interac-
tion with some fatty acid carriers such as p-FABPpm (Campbell
and Dutta-Roy, 1995; Larque et al., 2006) and FATP4 (Larque et
al., 2006).
BeWo cells incubated with a p-FABPpm antibody reduced their
uptake of DHA and AA by 64 and 68%, respectively, while OA
uptake was only reduced by 32% (Campbell et al., 1997). These
ﬁndings suggest that p-FABPpm could be directly involved in
DHA and AA uptake. Nevertheless, the existence of p-FABPpm
has only been demonstrated by Dutta-Roy’s group and has not
even been genetically sequenced, so that more evidence concern-
ing the structure and function of this protein in the placenta is
needed.
When Larque et al. (2006) evaluated the association between
DHA dietary supplementation and placental transport protein
gene expression in pregnant women, they found that placental
FATP1 and FATP4 gene expressions were directly correlated with
the percentage of DHA in the placental and maternal plasma PL.
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Furthermore, FATP4 expression was signiﬁcantly correlated with
the DHA in the PL of fetal blood. These data suggest that FATP4
could be involved in the selective placental transport of DHA and
so of n−3 LCPUFA. FATP is a family of proteins that presents acyl-
coA-synthetase activity andmaydirectly translocate free fatty acids
across the membrane and also direct acyl-CoA conversion (Jia et
al., 2007), facilitating their metabolism within the cells.
LCPUFA could themselves have an important regulatory func-
tion in fatty acid trophoblast uptake and metabolism through
the direct modiﬁcation of intracellular acyl-CoA-synthetase gene
expression (Johnsen et al., 2009), which could also inﬂuence
LCPUFA biomagniﬁcation in comparison with other fatty acids.
In an article published in Science, de Urquiza et al. (2000)
reported that DHA acts as a powerful activator of the retinoid
X receptor (RXR). Therefore, DHA may modulate fatty acid car-
rier expression through activation of RXR signaling pathways in
the placenta, brain or other tissue, and thus alter the expression
of adipophilin, acyl-CoA-synthetase, or other enzymes related to
lipid metabolism.
INTRACELLULAR MOVEMENT OF FATTY ACIDS WITHIN THE
PLACENTA
Once the fatty acids are in the cytosol, they bind to cytosolic fatty
acid-binding proteins (FABP) for movement. Richieri et al. (2000)
studied FABP afﬁnity and did not observe any particular fatty
acid afﬁnity, although the authors described how the afﬁnity was
reduced with short chain fatty acids and increased as the num-
ber of double bonds increased. Nine FABP have been identiﬁed
in mammals, with different tissue expression patterns and with
common and speciﬁc functions (Storch and Corsico, 2008).
Fatty acid-binding protein structure-function studies suggest
that the three-dimensional changes that result from fatty acid
binding may determine the particular function of the FABP
(Storch and McDermott, 2009). In mammals, FABPs are believed
to act in the cytoplasmic compartment by means of speciﬁc
interactions with subcellular organelles, including the endoplas-
mic reticulum, mitochondria, lipid droplets (LDs), and peroxi-
somes. Coordinate function with the membrane fatty acid carrier
FAT/CD36 and the cytosolic enzyme hormone-sensitive lipase
(HSL) have also been reported (Figure 4). FABPs are also likely
to function in the nucleus through the delivery of speciﬁc lig-
ands to nuclear transcription factors, such as the peroxisome
proliferators-activated receptors (PPAR; reviewed by Storch and
Corsico, 2008).
The following FABPhave beendescribed in the placenta: FABP1
or liver FABP (L-FABP), FABP3 or heart FABP (H-FABP), FABP4
or adipocyte FABP (A-FABP), FABP5 or keratinocyte FABP (K-
FABP), and FABP7 or brain FABP (B-FABP; Cunningham and
McDermott, 2009).
Campbell et al. (1998) were the ﬁrst to describe L-FABP
and H-FABP expression in human syncytiotrophoblast. Biron-
Shental et al. (2007) detected L-FABP, A-FABP, and H-FABP gene
expression in primary human trophoblast and in placental tis-
sue. However, the presence of A-FABP in macrophages has been
described (Storch and Corsico, 2008), and it would be interesting
to know the localization of A-FABP in the placenta (trophoblast or
macrophages). As regards B-FABP expression in the trophoblast,
two recent studies provided discrepancies in their results (Larque
et al., 2006; Biron-Shental et al., 2007).
STORAGE OF FATTY ACIDS IN LIPID DROPLETS
Non-esteriﬁed fatty acids can be oxidizedwithin trophoblast or re-
esteriﬁed and stored as TGandother lipid fractions in the placental
cells. As in other cells, excessive cellular concentrations of NEFA
are toxic and, to avoid toxicity, fatty acids are esteriﬁed with glyc-
erol, and the resulting TG deposited in LDs. Later, the fatty acids
can be released from cellular LD by the action of TG hydrolases in
a process called lipolysis (Coleman and Haynes, 1987; Haggarty et
al., 1999; Larque et al., 2006). The differential fatty acid processing
inside the placenta may also affect the rate of fatty acid transfer to
the fetal circulation.
Lipid droplets
The basic structure of the LD is similar to that of lipoproteins: a
hydrophobic core of neutral lipids (TG and CE) surrounded by a
membrane monolayer of PL with associated coat proteins. While
FIGURE 4 | Potential functions of fatty acid-binding proteins (FABPs) in intracellular fatty acid disposition. In Storch and Corsico (2008).
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lipoproteins and LDs both contribute to neutral lipid trafﬁcking,
their functions are different. Lipoproteins participate in extracel-
lular lipid trafﬁcking, while LDs are conﬁned to the cytoplasm,
where they mediate intracellular lipid storage, and metabolism.
Together with membrane bilayers, LDs represent one of the two
major intracellular lipid reservoirs (Ackerman et al., 2007).
Lipid droplets exhibit a marked heterogeneity regarding size,
cellular location, and associated protein composition within a
given cell or between different tissues. Recent advances in our
understanding of LD formation and function have emphasized
the importance of LD-associated proteins, the so-called PAT fam-
ily. PAT is a family of proteins who were initially constituted by
three members: Perilipin (with 3 isoforms A, B, C), Adipophilin
(or adipocyte differentiation-related protein, ADRP), and tail-
interacting protein of 47 kDa (TIP47). Two other proteins, S3–12
and oxidative tissues-enriched PAT protein (OXPAT), or myocar-
dial lipid droplet protein (MLDP) or lipid storage droplet protein
5 (LSDP5), were further bound to the PAT family in mice and
humans (Bickel et al., 2009).
PAT proteins protect the neutral lipids stored in the LD from
hydrolysis by cytoplasmatic lipases. It is known that only perilipin,
among mammal PAT proteins, changes its activity depending on
whether it has been phosphorylated by protein kinase A (PKA)
or not. In the basal state, perilipin inhibits TG hydrolysis in
adipocytes. However, upon phosphorylation, the role of perilipin
A shifts from storage to the mobilization of stored neutral lipids,
promoting lipolysis.
In recent years, the newly discovered protein–protein inter-
actions between perilipin and the intracellular lipases adipose
triglyceride lipase (ATGL) and HSL, as well as the ATGL activator
comparative gene identiﬁcation-58 (CGI-58), have provided clues
as to how perilipin might organize lipolysis, although the exact
mechanisms remains unclear (Zimmermann et al., 2009). On the
other hand, adipophilin would impair the lipolysis, preventing the
association of these lipases to LD, although the regulation of this
mechanism remains to be elucidated (Bickel et al., 2009). Never-
theless, in contrast to adipocytes and monocytes, trophoblast cells
are not specialized for lipid storage, and the role of the PAT fam-
ily (especially, adipophilin, perilipin) in the trophoblasts might
even differ from their role in other cell types. Better knowledge
of the activity of these proteins in the placenta would improve
our understanding of the fatty acid transport process in this
tissue.
Adipophilin is expressed in human villous trophoblast,where it
inhibits the process of lipolysis (Bildirici et al., 2003). Furthermore,
the expression of adipophilin is regulated by PPARγ, a protein
that plays a crucial role in the development of the rodent fetal–
placental unit and in human trophoblast differentiation (Barak
et al., 1999; Schaiff et al., 2000). PPARγ ablation is associated with
a reduced number of LD in rodent placenta (Barak et al., 1999),
which suggests that the trophoblast fatty acid accumulation is nec-
essary in LD formation, and that it is regulated during trophoblast
differentiation and placental development.
DHA might regulate its own metabolic intracellular metabo-
lism, through the control of lipolysis. LCPUFA are more efﬁcient
at stimulating the expression of adipophilin mRNA in BeWo cells
than short chain fatty acids (Tobin et al., 2006). In one study,
Suzuki et al. (2009) described that the incubation of BeWo cells
with DHA, induced adipophilin expression, by acting as an ago-
nist of the RXR. BeWo cells incubated with oleic acid showed a
greater accumulation of TG and LD than when incubated with
DHA; however, DHA transfer through the BeWo cell layer was
four times higher than the corresponding transfer of oleic acid;
Tobin et al. (2009) suggested that the lower accumulation of DHA
in the LD may result in a greater placental transfer.
Lipolysis
The current evidence suggests that intracellular TG hydrolysis
occurs in a sequential way that involves different lipases. The prin-
cipal TG-catabolic enzymes are the HSL and ATGL (reviewed in
adipocytes by Zimmermann et al., 2009).
Waterman et al. (1998) First identiﬁed the existence of HSL
(pH 6.0) in placental cytosol. HSL it is an intracellular enzyme
and is active in energy demanding processes. It is activated
through phosphorylation, which may be mediated by several hor-
mones including catecholamines, growth hormone, serotonin,
and glucagon, while insulin inactivates it by dephosphorylation.
HSL has been shown to exhibit broad substrate speciﬁcity, and
is capable of hydrolyzing cholesterylester, tri-, di-, and mono-
acylglycerol, retinyl ester, and numerous water soluble ester sub-
strates. The last step of the lipolysis is accomplished by mono-
glyceride lipase (MGL), which hydrolyses monoglycerides to form
glycerol and to release a free fatty acid. Lindegaard et al. (2006)
found an increase in HSL and EL mRNA expression in the pla-
centa of diabetic women, which could reﬂect the movement of
fatty acids to the fetus that occurs in diabetic pregnancies.
Adipose triglyceride lipase selectively performs the ﬁrst step in
TG hydrolysis, resulting in the formation of diacylglycerol (DG)
and NEFA. However, to date, ATGL has not been identiﬁed in the
placenta, although its possible involvement in the regulation of the
placental transfer of fatty acids, cannot be excluded.
Exportation of fatty acids from placental tissue to fetal circula-
tion. The most efﬁcient system to transport lipids from tissues
to blood involves the synthesis and secretion of apoB-containing
lipoproteins. These lipoproteins can contain large amounts of TG
and also act as carriers of essential lipids (lipophilic vitamins and
glycolipids; Davis, 1999). Madsen et al. (2004) demonstrated that
human placenta may synthesize and produce apoB, as well as a
kind of lipoprotein that could transport lipids to the fetal cir-
culation. However, the extent of placental lipoprotein secretion
capacity is still controversial, and most studies indicate that the
placenta transports intracellular fatty acids to the fetal circulation
directly through facilitated diffusion or via fatty acids transport
proteins, FAT/CD36, and FATP, located in the syncytiotrophoblast
basal membrane (Hanebutt et al., 2008).
Once in the fetal circulation, the fatty acids bind to α-
fetoprotein and reach the liver where they are re-esteriﬁed and
exported to the fetal circulation within the lipoproteins (mainly
as TG). The placenta may re-accept NEFA but not esteriﬁed fatty
acids. The selective esteriﬁcation of LCPUFA within the fetal cir-
culation has been suggested as another possible mechanism for the
selective accumulation of certain LCPUFA in the fetal circulation
(Kuhn and Crawford, 1986).
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PLACENTAL FATTY ACID TRANSFER IN COMPLICATED
PREGNANCIES
An impaired materno-fetal LCPUFA transport may occur in preg-
nancies that are complicated by abnormal placental function, for
example GDM or IUGR (Gauster et al., 2007). GDM is a patholog-
ical condition in which glucose intolerance is ﬁrst detected during
pregnancy. In GDM a signiﬁcant discrepancy between normal
LCPUFA contents in erythrocyte and plasma phospholipids of the
mother but reduced LCPUFA contents in plasma phospholipids
of the neonate has been reported (Wijendran et al., 1999, 2000;
Thomas et al., 2004). These data suggest that LCPUFA transport
from the placenta to the fetal circulation could be impaired in
women with gestational diabetes. The poor LCPUFA status in the
newborns of diabetic mothers could in part be responsible for the
delayed brain maturity in these newborns compared to controls.
Indeed, maternal diabetes during pregnancy has been reported
to affect behavioral and intellectual development in the offspring
(Rizzo et al., 1991). Pregestational or GDM was found to adversely
affect attention span and motor function of the offspring at school
age (Ornoy et al., 2001). These effects were negatively correlated
with the degree of maternal glycemic control. Thus, it will be
important to explore in future studies the extent to which fatty
acid transfer is altered by diabetes in pregnancy, and whether such
alterations can be overcome by adaptation of maternal dietary
intake.
The placental transfer of n−3 LCPUFA during pregnancy may
inﬂuence the neurological development of the fetus and several
studies have shown an association between maternal plasma DHA
status, dietary intake of DHA during gestation, and the develop-
ment of cognitive functions in the neonate and thereafter in the
child (Helland et al., 2001, 2003; Hibbeln et al., 2007). The inﬂu-
ence of dietary fatty acids on the activity of fatty acid carriers and
enzymes relatedwith lipolysis and lipid storagewithin the placenta
is under evaluation in pregnancies showing normal and abnormal
placental function.
In conclusion, numerous mechanisms have evolved to pro-
tect human offspring from LCPUFA deﬁciency in the maternal
diet during pregnancy. Placental tissue preferentially take up LCP-
UFA from the maternal circulation and regulate their transfer to
fetal circulation. However the mechanisms used for such regu-
lation are still under evaluation. The study of enzymes related
to fatty acid metabolism within the placenta in normal and
abnormal placentas may contribute in the future to clarifying
the relevance of the different steps for the preferential transfer
of LCPUFA and future nutritional strategies to improve health in
neonates.
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